Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Enters $5B Credit Agreement

NEW YORK – In a document filed with the US Securities and Exchange Commission on Thursday, Abbott Laboratories said it had entered a five-year, $5 billion revolving credit agreement with JP Morgan Chase as the administrative agent.

Under the agreement, Abbott can borrow up to $5 billion on an unsecured basis and any borrowings will mature and be payable five years from the effective date, Nov. 12, 2020. The borrowings will bear interest based on either a base rate or a Eurodollar rate, the filing said. 

Upon entering the agreement, Abbott ended its outstanding five-year, $5 billion credit agreement from Nov. 30, 2018, that also had JP Morgan Chase as administrative agents. There were no outstanding borrowings at that time, Abbott said.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.